|Tuesday, 27 February 2018, 09:33 HKT/SGT|
|Jointly Developed by Eisai and Saint-Plus|
TOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today.
According to the Ministry of Health, Labour and Welfare, the number of people with dementia was approximately 4.62 million in 2012, and is expected to increase to approximately 7 million by 2025. According to a survey on dementia conducted by Eisai of 224 men and women aged 40 and older, the highest source of anxiety was "personal or family member's incidence of dementia" followed by "burden of nursing care on family" and "financial burden caused by dementia care," while the top three factors for reducing anxiety were "consulting with healthcare and nursing care professionals, the government and other organizations," "preparing savings and other finances" and "obtaining information on preventing dementia."
Eisai and Saint-Plus entered into a joint development agreement for insurance that aims to reduce anxiety over dementia in December 2016, and jointly developed "Dementia Support" small amount short-term insurance to provide for dementia. For beneficiaries aged 40 to 90, submitting an application is possible with a simple notice even after becoming certified as requiring long-term care and beneficiaries receive a lump-sum payment upon diagnosis of specific conditions such as organic dementia. In addition, as ancillary services, policyholders and beneficiaries may be provided with various kinds of useful information on dementia as well as introduced to services including telephone consultation services operated by the non-profit organization Alzheimer's Association Japan about matters such as symptoms of dementia and concerns about nursing care.
The sale of insurance, including provision of ancillary services, is handled by Saint-Plus, and Eisai receives royalties relating to joint development.
About "Dementia Support" Insurance to Provide for Dementia
Sales of "Dementia Support" insurance are conducted by Saint-Plus.
1. Provides assurance against organic dementia
2. Submitting an application is possible even after becoming certified as requiring long-term care
3. A medical certificate is not required from a physician, it is possible to apply with just a simple notice
4. There are three courses for benefit payments
5. Insurance premiums start from 163 yen per month (60 year old male: 200,000 yen rider course)
6. People aged 40 years old up to and including people aged 90 years old may apply
7. It is possible to continue up to age 100 by renewing the policy
Saint-Plus' website for product information: https://www.saint-plus-ins.co.jp/sasae/ (available in Japanese only)
For inquiries about the product, please contact Saint-Plus: 0120-786-765 (Weekdays 9:30 to 17:00, excluding Saturdays, Sundays, public holidays, the New Year and other holiday periods, for residents in Japan only)
About Saint-Plus Small Amounts and Short Term Insurance Co., Ltd.
The Saint-Care Group, which provides comprehensive health care services, hears the voices from the field of nursing care and welfare, and in wanting to provide a "new support framework" that will be useful to those who truly need nursing care and their families, Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. developed and markets Japan's first private nursing care insurance as a nursing care business.
For more information about Saint-Plus Small Amounts and Short Term Insurance Co., Ltd., please visit https://www.saint-plus-ins.co.jp/ (available in Japanese only)
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Public Relations Department,
Eisai Co., Ltd.
Feb 27, 2018 09:33 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Mar 22, 2019 10:37 HKT/SGT|
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease|
|Mar 22, 2019 10:23 HKT/SGT|
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases|
|Mar 21, 2019 23:25 HKT/SGT|
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease|
|Mar 12, 2019 07:43 HKT/SGT|
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia|
|Mar 7, 2019 11:30 HKT/SGT|
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan|
|Feb 27, 2019 10:52 HKT/SGT|
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan|
|Feb 21, 2019 13:50 HKT/SGT|
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa|
|Feb 13, 2019 08:29 HKT/SGT|
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy|
|Feb 4, 2019 11:57 HKT/SGT|
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study|
|Jan 30, 2019 15:22 HKT/SGT|
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa|
|More news >>|